Daniel L. Spitz

701 total citations
16 papers, 300 citations indexed

About

Daniel L. Spitz is a scholar working on Reproductive Medicine, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Daniel L. Spitz has authored 16 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Reproductive Medicine, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Daniel L. Spitz's work include Ovarian cancer diagnosis and treatment (9 papers), Endometrial and Cervical Cancer Treatments (4 papers) and Cancer Genomics and Diagnostics (4 papers). Daniel L. Spitz is often cited by papers focused on Ovarian cancer diagnosis and treatment (9 papers), Endometrial and Cervical Cancer Treatments (4 papers) and Cancer Genomics and Diagnostics (4 papers). Daniel L. Spitz collaborates with scholars based in United States, Canada and Belgium. Daniel L. Spitz's co-authors include Mark E. Baker, James B. Hall, Linda F. Carson, Linda Van Le, Maurie Markman, Sheldon Weiner, Ignace Vergote, Charles H. Pippitt, John P. Micha and G. Dark and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Daniel L. Spitz

15 papers receiving 290 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel L. Spitz United States	7	157	128	83	81	64	16	300
Noriko Sasahara Japan	10	107 0.7×	109 0.9×	61 0.7×	77 1.0×	92 1.4×	17	307
Sayaka Ueno Japan	10	98 0.6×	85 0.7×	85 1.0×	62 0.8×	95 1.5×	29	309
Christopher McCann United Kingdom	11	136 0.9×	117 0.9×	187 2.3×	82 1.0×	80 1.3×	20	395
ME Sherman United States	5	145 0.9×	81 0.6×	116 1.4×	37 0.5×	50 0.8×	6	348
Domenico Priolo Italy	6	169 1.1×	169 1.3×	92 1.1×	97 1.2×	45 0.7×	9	364
Luisa Sánchez‐Lorenzo Spain	7	67 0.4×	190 1.5×	92 1.1×	24 0.3×	20 0.3×	23	288
Margaret Hill United States	5	175 1.1×	134 1.0×	107 1.3×	35 0.4×	24 0.4×	9	305
Lingfang Xia China	15	170 1.1×	172 1.3×	118 1.4×	93 1.1×	205 3.2×	35	485
Yapei Zhu China	11	57 0.4×	63 0.5×	123 1.5×	65 0.8×	26 0.4×	15	284
Marion Deslandres France	8	28 0.2×	124 1.0×	57 0.7×	39 0.5×	59 0.9×	13	319

Countries citing papers authored by Daniel L. Spitz

Since Specialization

Citations

This map shows the geographic impact of Daniel L. Spitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel L. Spitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel L. Spitz more than expected).

Fields of papers citing papers by Daniel L. Spitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel L. Spitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel L. Spitz. The network helps show where Daniel L. Spitz may publish in the future.

Co-authorship network of co-authors of Daniel L. Spitz

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel L. Spitz. A scholar is included among the top collaborators of Daniel L. Spitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel L. Spitz. Daniel L. Spitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Valabrega, Giorgio, Ignace Vergote, Debra L. Richardson, et al.. (2025). Longer-Term Safety And Efficacy Of Selinexor Maintenance Therapy For Patients With TP53wt Advanced Or Recurrent Endometrial Cancer: Follow-Up Subgroup Analysis Of The ENGOT-EN5/GOG-3055/SIENDO Study. International Journal of Gynecological Cancer. 35(2). 100081–100081. 1 indexed citations

Spitz, Daniel L., et al.. (2025). P-1299. Epidemiology of Invasive Meningococcal Disease in the United States: Review of Recent Data and Identified Risk Factors. Open Forum Infectious Diseases. 12(Supplement_1).

Makker, Vicky, José Alejandro Pérez Fidalgo, Alice Bergamini, et al.. (2022). Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification.. Journal of Clinical Oncology. 40(16_suppl). 5511–5511. 9 indexed citations

Piha‐Paul, Sarina A., Matthew H. Taylor, Daniel L. Spitz, et al.. (2019). Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study. Oncotarget. 10(60). 6526–6535. 20 indexed citations

Moore, Kathleen N., Setsuko K. Chambers, Erika Hamilton, et al.. (2019). Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.. Journal of Clinical Oncology. 37(15_suppl). 5513–5513. 18 indexed citations

Moore, Kathleen N., Karen A. Cadoo, Suzanne K. Chambers, et al.. (2017). A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Annals of Oncology. 28. v352–v353. 2 indexed citations

Rustin, Gordon, Ignace Vergote, John P. Micha, et al.. (2017). A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer. Gynecologic Oncology. 147(2). 276–282. 5 indexed citations

Piha‐Paul, Sarina A., James A. Knost, Fadi S. Braiteh, et al.. (2015). Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program.. Journal of Clinical Oncology. 33(15_suppl). 2516–2516. 3 indexed citations

Overton, Lindsay, Christopher L. Corless, Manish Agrawal, et al.. (2014). Impact of next-generation sequencing (NGS) on treatment decisions in the community oncology setting.. Journal of Clinical Oncology. 32(15_suppl). 11028–11028. 1 indexed citations

10.

García, Agustin A., Vicky Makker, Daniel L. Spitz, et al.. (2014). Trc105 (Anti-Endoglin Antibody) in Combination with Bevacizumab (Bev) and As a Single Agent for Platinum Resistant Ovarian Cancer. Annals of Oncology. 25. iv310–iv310. 1 indexed citations

11.

Giles, Frank, Sarina A. Piha‐Paul, Alexander I. Spira, et al.. (2014). The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients. Blood. 124(21). 4818–4818. 1 indexed citations

12.

Vergote, Ignace, Agustin A. García, John P. Micha, et al.. (2013). Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer. Journal of Clinical Oncology. 31(32). 4060–4066. 34 indexed citations

13.

García, Agustin A., Ignace Vergote, John P. Micha, et al.. (2011). The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD).. Journal of Clinical Oncology. 29(15_suppl). 5047–5047. 4 indexed citations

14.

Vergote, Ignace, John P. Micha, Charles H. Pippitt, et al.. (2010). Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.. Journal of Clinical Oncology. 28(15_suppl). 5013–5013. 17 indexed citations

15.

Markman, Maurie, James B. Hall, Daniel L. Spitz, et al.. (2002). Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer. Journal of Clinical Oncology. 20(9). 2365–2369. 178 indexed citations

16.

Spitz, Daniel L., et al.. (1988). Unmasking of cryptic natural killer (NK) cell recognition sites on chronic lymphocytic leukemia lymphocytes. American Journal of Hematology. 28(3). 155–161. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact